toxSYN™ ADC Payload Platform
The toxSYN™ platform comprises ADC payloads that span multiple modes of action and where the majority are clinically validated. Together with the company’s other ADC enabling technologies, these offer a consolidated licensing solution for translating any antibody into a highly competitive, proprietary ADC product.
Each toxSYN™ linker-payload is functionalized to allow facile conjugation using the company’s GlycoConnect™ technology. Furthermore, these may include linkers that are of non-cleavable or cleavable nature (i.e. designed for intracellular/lysosomal release of the active catabolite).
Mode-of-Action | toxSYN™ Linker-Payload |
Payload (Active Catabolite) |
---|---|---|
Topoisomerase inhibition | SYNtecan™ P | undisclosed camptothecin |
DNA damaging | ||
SYNeamicin D™ P | calicheamicin γ1I | |
SYNeamicin G™ P | calicheamicin γ1I | |
Microtubule inhibition | SYNstatin E™ | MMAE |
SYNstatin F™ | MMAF | |
SYNtansine™ | maytansinoid * |
*N-6-aminohexanoyl-maytansine (Ahx-maytansine)
P Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™
PLEASE NOTE: these illustrations represent an artist’s rendition